title: [Malignomas of the nasal cavity and the paranasal sinuses: clinical characteristics, therapy and prognosis of different tumor types].
abstract: BACKGROUND
  Malignomas of the nasal cavity and the paranasal sinuses count for less than 3 % of the ENT-malignancies.
  
  
  METHODS
  This retrospective chart review reports about 46 patients that were first diagnosed and treated with a nasal cavity or paranasal sinus malignancy between 1998 and 2002 in the ENT department of the Ruhr-Universität Bochum.
  
  
  RESULTS
  18 of 46 malignomas were squamous cell carcinomas. At initial diagnose, already 52 % of malignomas were staged T4. Accordingly the origin in 17 % of malignomas could not be determined anymore. Additional 43 % of malignomas originated from the nasal cavity, another 20 % from the maxillary sinus. 11 of 46 patients (24 %) showed histological proven nodal involvement at initial diagnose. 92 % of patients underwent surgical therapy. 25 patients were radiated postoperatively. Over-all 1-year-survival-rate was 75 %, over-all 2-year-survival-rate was 47 %. Beside patients age, tumor free margins at initial surgery and absence of nodal involvement correlated to improved survival. 16 (76 %) of the 21 patients who died had local recurrence. Maxillary sinus malignomas recurred more often than malignomas of the ethmoid and the nasal cavity.
  
  
  CONCLUSIONS
  Malignancies of the nasal cavity and paranasal sinuses are very often diagnosed in advanced T-stages because of unspecific symptoms. The limited prognosis mainly depends on free surgical margins at the first resection and nodal involvement at the first diagnose. For improvement in outcome of nasal and paranasal sinuses malignancies, prospective multi-center trials are necessary.
authors.affiliation: Klinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Halschirurgie der Ruhr-Universität Bochum, Germany. Sara.Euteneuer@rub.de
authors.forename: S
authors.initials: S
authors.lastname: Euteneuer
authors.forename: H
authors.initials: H
authors.lastname: Sudhoff
authors.forename: M
authors.initials: M
authors.lastname: Bernal-Sprekelsen
authors.forename: D
authors.initials: D
authors.lastname: Theegarten
authors.forename: S
authors.initials: S
authors.lastname: Dazert
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003528:Carcinoma, Adenoid Cystic / Q000175:diagnosis / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D018304:Esthesioneuroblastoma, Olfactory / Q000175:diagnosis / Q000401:mortality; D005005:Ethmoid Sinus; D005260:Female; D005500:Follow-Up Studies; D005626:Frontal Sinus; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D010255:Paranasal Sinus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D013101:Sphenoid Sinus; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome